BF10

BF10 is an experimental **bifunctional immuno-oncology fusion protein** composed of an interleukin-10 payload fused to a colony-stimulating factor 1 receptor blocking antibody. Based on the cited publication context, the molecule is designed to concentrate IL-10 activity within the tumor microenvironment while simultaneously blocking CSF-1R-driven tumor-associated macrophage biology. In preclinical tumor models, especially head and neck cancer models, BF10 reduced tumor-associated macrophages and enhanced intratumoral CD8-positive T-cell proliferation, activation, metabolic reprogramming, and T-cell receptor clonotype diversity, shifting the tumor microenvironment toward a more immune-active state. The available context supports BF10 as a preclinical antitumor biologic rather than an approved medicine, and no clear company sponsor, trade name, or clinical-stage development program is explicitly identified from the provided source alone.

Other names

CSF-1R-blocking antibody/IL-10 fusion protein